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BACKGROUND: Thymic carcinoma (TC) is a rare aggressive tumour. Median survival with current treatments is only 2 years. Sunitinib is
a multi-targeted tyrosine kinase inhibitor that has shown benefit in various other cancers.
METHODS: Laboratory analyses of snap-frozen tumour tissues were performed to detect activation and genetic mutations of receptor
tyrosine kinases (RTKs) in TC samples. On the basis of molecular analyses showing activation of multiple RTKs in their tumour, four
patients with metastatic TCs refractory to conventional therapies were treated with sunitinib according to standard protocols.
RESULTS: RTK analysis in three of the patients showed activation of multiple RTKs, including platelet-derived growth factor-b and
vascular endothelial growth factor 3. Mutations of EGFR, c-KIT, KRAS, and BRAF genes were not found. Administration of sunitinib
yielded a partial remission (lasting 2 to 18þ months) according to the RECIST criteria in three patients and stable disease with
excellent metabolic response in 18F-FDG-PET in another one. The overall survival with sunitinib treatment ranges from 4 to 40þ
months. Withdrawal of the drug in one patient prompted rapid tumour progression that could be controlled by re-administration
of sunitinib.
CONCLUSIONS: Sunitinib is an active treatment for metastatic TC. A panel of molecular analyses may be warranted for optimal
patient selection.
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Thymic carcinoma (TC) is a rare aggressive tumour of the thymus
(Eng et al, 2004). It affects men nearly twice as often as women,
across a wide age range (Travis et al, 2004). Patients often initially
present with cough and chest pain. Further work-up usually
reveals a mediastinal mass. Histologically, TCs are rather
heterogeneous and resemble tumours found in other organs
(Travis et al, 2004). The prognosis is generally poor, and the
majority of patients develop recurrences. Lymph nodes, lungs,
liver, and bones are common sites for metastases. Patients with TC
have a median survival of 2 years (Eng et al, 2004).
The optimal management of TCs remains an unresolved
question, because of their rarity and aggressiveness (Kurup and
Loehrer, 2004). Complete surgical resection substantially improves
survival rates, but this is not always possible, because of invasion
of surrounding structures or metastasis (Wright and Kessler,
2005). Adjuvant radiation with 40–70Gy often follows surgical
resection, but a survival advantage for radiotherapy has not been
clearly demonstrated (Korst et al,2 0 0 9 ) .C h e m o t h e r a p yw i t h
regimens containing cisplatin have often yielded partial remissions
(Evans and Lynch, 2005), but some patients do not respond at all and
most patients do not achieve long-lasting remission. Thus, many
patients eventually cannot be helped by any currently available
treatments, and they succumb to the tumour’s rapid progression.
Targeted molecular therapy is a new paradigm in cancer
treatment, in which drugs selectively interfere with molecules
considered important in oncogenesis. Whereas conventional
chemotherapy aims to kill all proliferating cells including tumours,
targeted molecular therapy aims to disrupt cancer-specific
signalling pathways involved in tumour growth and proliferation
(Faivre et al, 2006). Compared with the toxicity of chemotherapy,
targeted molecular therapies seem to be relatively tolerable
(Rutkowski and Ruka, 2009). There are multiple types of targeted
molecular therapies, but among them, multi-target tyrosine
kinase inhibitors have received particular attention. Tyrosine
kinases regulate important cell functions, including survival,
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sdifferentiation, and proliferation (Faivre et al, 2006). When
mutated or overexpressed, they have key roles in many cancers:
increasing tumour cell growth and proliferation, inducing
resistance to apoptosis, and promoting angiogenesis and
metastasis.
Sunitinib (Pfizer, New York, NY, USA) is a potent multi-target
tyrosine kinase inhibitor, designed to selectively block the
intracellular receptor-binding sites of several tyrosine kinases:
vascular endothelial growth factors 1–3 (VEGF1–3), FMS-like
tyrosine kinase 3 (FLT3), stem cell growth factor (c-KIT), platelet-
derived growth factors-a and -b (PDGFa–b), colony-stimulating
factor 1 (CSF1), and the ‘RET’ receptor for glial-derived
neurotrophic factors (Faivre et al, 2007). Inhibition of these
tyrosine kinase receptors is believed to ultimately result in tumour
regression primarily through anti-angiogenic effects and also
through direct tumour cell apoptosis. In clinical trials, sunitinib
has been reported to be beneficial against metastatic clear-cell
renal carcinoma (Motzer et al, 2007), gastrointestinal stromal
tumour (Demetri et al, 2006), and advanced pancreatic neuroen-
docrine tumours (Kulke et al, 2008). The most commonly reported
adverse events (such as fatigue, diarrhoea, nausea, anorexia, skin
discolouration, and hand–foot syndrome) have been reported as
relatively tolerable (Faivre et al, 2007; Porta et al, 2007).
For TC, there have only been a few peer-reviewed journal papers
on any of the new targeted molecular therapies. We previously
reported a single case in which imatinib led to temporary
regression of liver metastases and stabilisation of the primary TC
(Strobel et al, 2004). Another case report briefly mentioned the
unsuccessful last-resort use of imatinib in a paediatric patient
(Kertesz et al, 2007). One paper reported a partial response of a
malignant thymoma to the abl/src kinase inhibitor dasatinib
(Chuah et al, 2006).
In addition, there have been two case reports on the successful
usage of sorafenib in heavily pre-treated, chemotherapy-resistant
metastatic patients (Bisagni et al, 2009; Li et al, 2009).
To our awareness, there have been no reports of using sunitinib
against any tumours of the thymus. The aim of this paper is to
report the clinical outcomes and laboratory findings from our
initial usage of sunitinib in metastatic TCs.
METHODS
Patients
Tumours were classified according to criteria of the WHO
classification (Travis et al, 2004). Patients with metastatic TCs
refractory to conventional treatment were considered eligible for
treatment with sunitinib and inclusion in this report. All patients
provided informed consent for treatment and reporting of their data.
Treatment
Patients were treated by interdisciplinary teams experienced in the
application of tyrosine kinase inhibitors. Dose selection of sunitinib
was dependent on tumour load, tumour progression slope, and
expected toxicity profile related to the patients’ co-medication and
medical history, not always following the 50mg per day, 4/2 regimen
(Faivre et al, 2007) (4 weeks on, 2 weeks off treatment, see details
below). Toxicity and response were closely monitored, to adjust the
dosage or cycle length if required. Other concurrent therapies were
used whenever indicated. Tumour response was assessed according
to the revised RECIST criteria (Eisenhauer et al, 2009). Further
medical history and adverse events were charted.
Laboratory analyses
Native tumour samples were available from patients A–C and kept
snap frozen and stored at  801C for molecular analyses. Paraffin
sections were stained by a standard avidin–biotin peroxidase
technique. Primary antibodies included CD5, c-KIT, and ki67.
The Human Phosopho-Receptor Tyrosine Kinase Array Kit
(R&D Systems, Wiesbaden, Germany) was used according to the
manufacturer’s instructions to simultaneously detect the relative
tyrosine phosphorylation levels of 42 different receptor tyrosine
kinases (RTKs), as described previously in more detail (Ball et al,
2007).
Both DNA and RNA were extracted and amplified by PCR using
commercial kits (QiAamp DNA FFPE and RNeasy FFPE; Qiagen,
Hilden, Germany) according to the manufacturer’s instructions.
c-KIT (exons 9, 11, 13, 17), EGFR (exons 18–21), KRAS (exon 2),
and BRAF (V600E) were sequenced according to standard
procedures (details available upon request).
RESULTS
Laboratory findings
In addition to histomorphological criteria, CD5 and c-KIT were
strongly expressed in all cases, providing very strong evidence that
these were indeed primary TCs (Travis et al, 2004).
Case A mainly showed activation of the EGFR, with a very weak
signal for the insulin receptor (IR), KIT, and Ephrin B2 (Figure 1).
Case B showed strong activation of several RTKs, including IR and
insulin-like growth factor receptor 1, fibroblast growth factor
receptor 2, KIT, Erb4, and RET (Figure 1) Case C showed
activation of ErB4, Tyro3/Dtk, and RON (Figure 1).
Using PCR and direct sequencing of the resulting amplification
products, no mutations were found for c-KIT, KRAS, BRAF,o r
EGFR (not shown).
Patients
The patients’ basic sociodemographic and clinical characteristics are
presented in Table 1. Three patients in Table 1 were metastatic at the
initial diagnosis. The patients’ earlier history of cancer and treatment
is summarised in Table 2. In brief, all patients had already reached a
point of having metastases not responding to established treatment
options, before they were started on sunitinib.
Clinical outcomes
For patient A, sunitinib was administered for 2 years, 9 months at
















Figure 1 Phospho-protein arrays of tumour samples from patients A–C
with 42 spotted receptor tyrosine kinases (signal indicates activated
protein). Tumour sample of patient A shows strong activation of EGFR (1)
and weaker signals for EphB2 (2), KIT (3), and the insulin receptor (4).
Tumour sample of patient B shows moderate signals for RON (5), Erb4 (6),
FGFR2 (7), KIT (8), and strong signals for insulin receptor (9), IGF1R (10),
and RET (11). Tumour sample of patient C shows moderate signals for
RON (12), Erb4 (13), and Tyro3/Dtk (14).
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s‘off’ periods). After just 2 weeks, the patient’s abdominal pain
disappeared. The 18F-FDG-PET scans showed reduced glucose
metabolism of all liver metastases after 6 weeks in comparison with
pre-treatment values. After 6 months, the vessel density calculated
by FDG-PET of the liver metastases was reduced to o20% of their
pre-sunitinib levels (Figure 2A–B). As the primary tumour seemed
to respond less to the treatment than the liver metastases,
concurrent radionuclide treatment with DOTATOC was adminis-
tered during the 4th–11th months of sunitinib. Thereafter, the
vessel density of the metastases was still very low, and the
metastases were classified as stable disease according to RECIST
(Eisenhauer et al, 2009). After 22 months of sunitinib treatment,
the liver metastases started to progress again with new lesions;
hence, selective infusional radiotherapy was started, resulting in a
PR. Another 8 months later (4 2009), the primary tumour was
completely resected, followed by 54Gy irradiation of the
mediastinum. As all known tumour lesions seemed to be under
control, sunitinib was discontinued in 7 2009. Three months later,
PET-CT showed massive progression of the hepatic metastases
(Figure 2C) and lymph node metastases at the coeliac axis.
Sunitinib was re-administered at 50mg per day in 10 2009. Two
months later, a control PET-CT showed marked regression of all
lesions, corresponding to PR (Figure 2D).
Patient B presented with asymptomatic liver metastases.
Sunitinib was started at the registered 50mg per day, 4/2 regimen.
The metastases were still progressing after one cycle but developed
a PR after another three cycles (Figure 3A and B). After four cycles
of 4/2, the cycling schedule was slowed to 4/4 because of side
effects during the ‘on’ phase, which resolved during the ‘off phase’.
After 10 months of therapy, the cycling was slowed to 4/6
for another two cycles, and further 4/8 dosage thereafter. At all
follow-up visits since the fifth cycle of sunitinib until the present
time (i.e., for 18 months), the liver metastases were still in good
partial remission, and there has been no evidence of relapse of the
primary tumour (Figure 3C).
Patient C presented with several metachronous asymptomatic
lung metastases. Owing to his significant co-medication for severe
NYHA III problems and hypertension, sunitinib was started at a
dose of 25mg per day. As the medication was well tolerated, the
dose was escalated to 37.5mg per day after 4 weeks and
antihypertensive medication was intensified. The CT controls at
7 months showed partial remission of his lung metastases (Figure
4A–C). As the patient later on developed leukopenia with a WBC
of o1800 cells per ml and anaemia, sunitinib was again decreased
to 25mg per day after 9 months. After 14 months under sunitinib
(2 2010), the patient is still in PR.
In patient D, who suffered from a particularly aggressive, widely
disseminated tumour at initial presentation, symptoms (such as
shortness of breath) improved after 2 weeks of sunitinib with
50mg per day, 4/2 dosing. Restaging after 6 weeks showed a PR of
the primary tumour and lung metastases. However, this was soon
followed by rapid tumour progression, to which the patient
succumbed 4 months after the start of sunitinib and 16 months
after initial diagnosis.







(start of sunitinib) Tumour grade
A M 35 IVb Squamous cell IVb 2
B M 69 IVa Squamous cell IVb 2
C M 77 II Squamous cell IVb 2
D F 28 IVb Undifferentiated IVb 3
Table 2 Previous treatment and result of sunitinib therapy
Patient Previous treatment




A Systemic chemotherapy, PR for 3 months,
imatinib 400/800mg PD
Primary tumour liver metastases (60% HR)
axillary, supraclavicular, and coeliac lymph
node metastases
SD






B Primary tumour resection, radiation to
mediastinum DFS 4 years, Systemic
chemotherapy for liver metastases, PD
Liver metastases PR
a PFS 18+ months
C Primary tumour resection, DFS 14 months Bilateral lung metastases PR
a PFS 14+ months
D Systemic chemotherapy, radiation of retinal
metastases, PR for 6 months
Primary tumour, multiple bone and lung
metastases (all PD)
PR
a for 2 months OS 4 months
Abbreviations: PR¼partial remission; PD¼progressive disease; HR¼hepatic replacement; SD¼stable disease; OS¼overall survival; DFS¼disease-free survival;
PFS¼progression-free survival.
aAcc to RECIST (Response Evaluation Criteria In Solid Tumors) criteria.
Figure 2 PET scans of the primary tumour and liver metastases from
patient A. (A) Baseline just before initiating sunitinib. (B) After 6 months
(in 4 2007) sunitinib. (C) Three months after withdrawal of sunitinib
(10 2009) showing a highly enriched index metastasis. (D) The same lesion
was undetectable 2 months after re-administration of sunitinib (12 2009).
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Commonly reported side effects of sunitinib were also observed in
our patients. Nausea was present in three patients. Hypertension
and fatigue were present in patients A and C. Weakness and
oedema were present in patients C and D. Patient D had some
minor, non-relevant electrophysiological cardiac alterations, but
no hypertension or haematological complications. Grade 2/3
hand–foot syndrome in patient B lead to prolonged ‘off’ phases
in the treatment cycles to allow for recovery.
DISCUSSION
Thymic carcinoma is a rare tumour that is difficult to treat in
advanced stages. Cisplatin-based multi-agent chemotherapy can be
beneficial, but often the responses do not last long. There is
currently no other established second-line treatment for TC.
Targeted molecular therapy could open new therapeutic options in
these patients.
Our initial experience shows that sunitinib seems promising for
patients with metastatic TC. The rationale for choosing this drug
came from our observation that three of the available tumour
samples showed simultaneous activation of multiple RTKs. Hence,
it seemed reasonable to interfere with several of these processes
concurrently to prevent tumour escape mechanisms through
alternative signalling pathways (Faivre et al, 2006; Potapova
et al, 2006).
The new targeted molecular therapies are clinically effective
because they have been designed to disrupt the cellular signalling
pathways involved in various aspects of oncogenesis, such as
growth signal transduction, cell invasion, evasion of apoptosis, and
metastatic dissemination. Sunitinib was originally designed and
developed for its high potency against VEGFR2 and PDGFR-b
(Burstein et al, 2008), and it is known to block the intracellular
ATP-binding sites of several other RTKs: VEGF1, VEGF3, FLT3,
c-KIT, PDGFa, CSF1, and RET (Faivre et al, 2007). Thus, on the
basis of past scientific knowledge (Chow and Eckhardt, 2007) as
well as our clinical observations and laboratory results, it seems
plausible that the predominant mechanism of action of sunitinib in
our patients was anti-angiogenesis, even though its main known
targets were not prominently activated in the tumour samples
studied herein. However in case A, the patient’s PET scans showed
a rapid and substantial reduction in tumour vessel density after the
initiation of sunitinib, consistent with an anti-angiogenic mechan-
ism of action. Many other RTKs also promote angiogenesis
indirectly (Al-Nedawi et al, 2009) and thus could account for this
finding. Taken together, the clinical observations, laboratory
analyses, and previous molecular knowledge on sunitinib are
consistent in supporting the view that sunitinib’s effectiveness in
these cases was due primarily to anti-angiogenesis.
Nonetheless, sunitinib may have had other mechanisms of
action, in addition to anti-angiogenesis or instead of it. Sunitinib
blocks many more RTKs than the literature or the manufacturer
currently discusses. Furthermore, our array only tested for 42 of
B300 RTKs; hence, many other RTKs may have been activated in
our patients. Further clinical studies will be required to analyse the
underlying mechanisms more thoroughly.
Although our findings are limited by the small sample
size, sunitinib seems to be a particularly good choice of second-
line therapy for patients with metastatic TC. The tumours
reported in this study were histologically and immunohisto-
chemically comparable and representative for a majority of
TCs in the broader population. Moreover, in line with previous
reports (Tsuchida et al, 2008; Yoh et al, 2008), there were no
mutations of c-KIT, KRAS, BRAF,o rEGFR; therefore,
apparently the effectiveness of sunitinib does not depend on such
abnormalities.
Our initial observations suggest that sunitinib (and possibly also
other multi-kinase inhibitors such as sorafenib (Bisagni et al,
2009)) may be more effective against TC than the disappointing
results reported in the grey literature for single-target molecular
therapies, such as gefinitinib (Kurup et al, 2005), erlotinib (Bedano
et al, 2008), and imatinib (Salter et al, 2008). These earlier
results seem plausible in the light of the broad and rather
heterogeneous spectrum of activated RTKs in the few samples
described in this study.
Our ‘index’ patient A provides very strong circumstantial
evidence that sunitinib was able to control his disease over more
than 3 years and even at relapse of sunitinib pre-treated
metastases. Similar favourable findings in two other patients
(BþC) indicate that sunitinib may be able to block tumour escape
mechanisms and may be a promising option for long-term
treatment. Patient D (with an unusually aggressive tumour)
obtained a temporary partial remission, which we estimate
prolonged her life by about 1–3 months. It is noteworthy that
although tumours from patients A–C were ‘classical’ squamous
Figure 3 CT scans of a representative liver metastasis from patient B. (A) Liver metastasis at baseline just before initiating sunitinib. (B) Liver metastases
after 6 months sunitinib. (C) Liver metastases after 18 months sunitinib.
Figure 4 CT scans of an index lung metastasis from patient C. (A) Lung metastasis (square) at baseline just before initiating sunitinib. (B) Lung metastasis
after 3 months sunitinib. (C) Lung metastasis after 7 months sunitinib.
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scell TCs, the tumour from patient D was undifferentiated and had
unusually high mitotic counts, prompting us to rule out EBV
association or a so-called ‘carcinoma with t(15;19) translocation’
(French et al, 2003) at initial presentation by respective molecular
techniques.
In conclusion, sunitinib could be a promising new treatment
option for TCs. Compared with many other tumours such as
advanced prostate cancer (Dror Michaelson et al, 2009), metastatic
colorectal cancer (Saltz et al, 2007), metastatic breast cancer
(Burstein et al, 2008), or advanced non-small-cell lung cancer
(Socinski et al, 2008), in which sunitinib was either inefficient
or had only weak benefits were overridden by serious risks, TC
seems to be one of the types of cancer that is responsive to
sunitinib. It will be important to investigate whether patients with
malignant thymomas may also benefit from this drug.
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